GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates
DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) — GH Research PLC (Nasdaq:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2022 and gave updates on its business.
Related news for (GHRS)
- Primary Endpoint Met in GH Research’s Phase 2b GH001Trial in TRD
- GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression
- GH Research Reports Full Year 2022 Financial Results and Provides Business Updates
- GH Research Reports Full Year 2022 Financial Results and Provides Business Updates
- GH Research Provides Business Updates and Highlights Key Upcoming Milestones